1. General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT(2020), PA/PH/OMCL (13) 82, R5/Verification of Analytical Procedures,https://www.edqm.eu/documents/52006/128968/omcl-validation-verification-of-analytical-procedures-paphomcl1382r5.pdf/5bd682ee-6c62-a352-c6ad-4cb2c31c749d?t=1628491790975. [accessed 22.04.2024].
2. European Medicines Agency (1995). CPMP/ICH/381/95), ICH Topic Q2 (R1) Validation of Analytical Procedures: Text and Methodology,https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-2-r1-validation-analytical-procedures-text-and-methodology-step-5_en.pdf [accessed 22.04.2024].
3. Autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: The randomized prospective, single-center, open-label TRITON study;Reinders;Am J Transplant,2021
4. Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial;van der Kooij;BMJ Open,2020
5. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study;van Balen;Front Immunol,2020